NAMPT and atherosclerosis: As only differences in situ visfatin levels were observed and in order to study whether these differences were only a local effect or if they were also reflected in serum, we measured visfatin circulating levels in the group of patients suffering from atherosclerosis and in a serum group of healthy subjects (n = 16).